# GTB-5550 in Advanced Solid Tumors

> **NCT07541573** · PHASE1 · RECRUITING · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 175 (estimated)

## Conditions studied

- Tri-specific Killer Engager
- Solid Tumor
- Advanced Solid Tumor

## Interventions

- **DRUG:** GTB-5550

## Key facts

- **NCT ID:** NCT07541573
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-08
- **Primary completion:** 2031-01
- **Final completion:** 2032-01
- **Target enrollment:** 175 (ESTIMATED)
- **Last updated:** 2026-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07541573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07541573, "GTB-5550 in Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07541573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*